Submit a Review & Earn an Amazon Gift Card
You can now submit reviews for your favorite Tocris products. Your review will help other researchers decide on the best products for their research. Why not submit a review today?!
Submit ReviewBIIB 021
Description: Selective Hsp90 inhibitor
Alternative Names: CNF 2024
Chemical Name: 6-Chloro-9-[(4-methoxy-3,5-dimethyl-2-pyridinyl)methyl]-9H-purin-2-amine
Purity: ≥98% (HPLC)
Biological Activity for BIIB 021
BIIB 021 is a selective, Hsp90 competitive inhibitor (Ki = 1.7 nM). Displays no significant activity at a range of ATP-binding kinases or Na+K+ ATPase. Induces degradation of HER-2 in vitro (EC50 = 38 nM in MCF-7 cells). Inhibits growth and promotes cell death in a variety of human tumor cells. Orally bioavailable.
Technical Data for BIIB 021
| M. Wt | 318.76 |
| Formula | C14H15ClN6O |
| Storage | Store at -20°C |
| Purity | ≥98% (HPLC) |
| CAS Number | 848695-25-0 |
| PubChem ID | 16736529 |
| InChI Key | QULDDKSCVCJTPV-UHFFFAOYSA-N |
| Smiles | ClC1=C2C(N(CC3=NC=C(C)C(OC)=C3C)C=N2)=NC(N)=N1 |
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
Tocris products are intended for laboratory research use only, unless stated otherwise.
Product Datasheets for BIIB 021
References for BIIB 021
References are publications that support the biological activity of the product.
Lundgren et al (2009) BIIB021, an orally available, fully synthetic small-molecule inhibitor of the heat shock protein Hsp90. Mol.Cancer Ther. 8 921 PMID: 19372565
Yin et al (2010) BIIB021, a novel Hsp90 inhibitor, sensitizes head and neck squamous cell carcinoma to radiotherapy. Int.J.Cancer 126 1216 PMID: 19662650
View Related Products by Target
View Related Products by Product Action
Keywords: BIIB 021, BIIB 021 supplier, BIIB021, heat, shock, proteins, 90, hsp90, inhibitors, chaperones, HER-2, antitumor, antitumour, CNF2024, inhibits, orally, bioavailable, potent, selective, CNF, 2024, Hsp90, 4608, Tocris Bioscience
1 Citation for BIIB 021
Citations are publications that use Tocris products. Selected citations for BIIB 021 include:
Catherine B et al (2021) Inhibition of the NLRP3 inflammasome by HSP90 inhibitors. Immunology 162 84-91 PMID: 32954500
Reviews for BIIB 021
Average Rating: 5 (Based on 1 Review.)
Have you used BIIB 021?
Submit a review and receive an Amazon gift card.
$50/€35/£30/$50CAN/¥300 Yuan/¥5000 Yen for first to review with an image
$25/€18/£15/$25CAN/¥75 Yuan/¥2500 Yen for a review with an image
$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image
Filter by:
BIIB 021 induces PARP cleavage in U2OS cells.
By
Anonymous on 03/25/2019
Assay Type: In Vitro
Species: Human
Cell Line/Tissue: Osteosarcoma
Human osteosarcoma, U2OS, cells were treated with BIIB 021 (1 microM) for 24 h to follow PARP cleavage using Western blot. BIIB 021 activated PARP cleavage in U2OS cells
Literature in this Area
Tocris offers the following scientific literature in this area to showcase our products. We invite you to request* your copy today!
*Please note that Tocris will only send literature to established scientific business / institute addresses.
Cell Cycle and DNA Damage Research Product Guide
This product guide provides a review of the cell cycle and DNA damage research area and lists over 150 products, including research tools for:
- Cell Cycle and Mitosis
- DNA Damage Repair
- Targeted Protein Degradation
- Ubiquitin Proteasome Pathway
- Chemotherapy Targets
Parkinson's Disease Poster
Parkinson's disease (PD) causes chronic disability and is the second most common neurodegenerative condition. This poster outlines the neurobiology of the disease, as well as highlighting current therapeutic treatments for symptomatic PD, and emerging therapeutic strategies to delay PD onset and progression.